Several Factors Predict Recurrence, Survival Among Patients With Pelvic Ewing Sarcoma
As the disease’s location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision–making.
|The following article features coverage from the Connective Tissue Oncology Society (CTOS) in Maui, Hawaii. Click here to read more of Cancer Therapy Advisor's conference coverage.|
Several factors, including soft tissue infiltration and complete affected bone removal, are associated with local recurrence (LR) and overall survival (OS) among patients with Ewing sarcoma of the pelvis, according to an oral presentation at the Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting.1
While Ewing sarcoma is one of the most common bone cancers in pediatric patients, pelvic Ewing sarcoma is rarer, accounting for only 20% of patients with the disease. As the disease's location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.
In a retrospective analysis of the Euro-EWING99 trial (ClinicalTrials.gov Identifier: NCT00020566), researchers reviewed data from 180 patients treated for pelvic Ewing sarcoma between 1998 and 2009. All patients were previously untreated for the disease and the median follow-up was 54 months.
The 5-year OS rate was 59% and the 5-year LR rate was 76%.
Patients with sacral tumors had favorable LR and OS rates compared with non-sacral tumors. Definitive radiotherapy for sacral tumors yielded similar LR and OS rates when compared with radiotherapy plus surgery.
Combined radiotherapy and surgery were, however, superior to surgery alone among patients with non-sacral tumors. Both poor response to chemotherapy and surgical complications predicted worse survival with non-sacral tumors.
Two notable findings for patients with non-sacral tumors were that soft tissue infiltration predicted for poor LR and OS rates, while complete affected bone removal predicted for improved LR and OS rates.
In an unexplained finding, undergoing biopsy and resection at the same institution was linked with a worse LR rate.
Read more of Cancer Therapy Advisor's coverage of the Connective Tissue Oncology Society (CTOS) by visiting the conference page.
- Andreou D, Ranft A, Baumhoer D, et al. The influence of local treatment on outcome of localized pelvic Ewing sarcoma - a retrospective analysis of the Euro-EWING99 trial. Oral presentation at: Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting. November 8-11, 2017; Maui, Hawaii.